Anti-CD20-Interferon-β fusion protein therapy of murine B-Cell lymphomas

Journal of Immunotherapy

Volumn 36, Issue 5, 2013, Pages 305-318

  Trinh, Kham R ^a   Vasuthasawat, Alex ^a   Steward, Kristopher K ^a   Yamada, Reiko E ^a   Timmerman, John M ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Immunotherapy; Interferon; Lymphoma; Rituximab; Tumor immunity

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 8; CASPASE 9; CD20 ANTIBODY; CD20 ANTIBODY INTERFERON BETA FUSION PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; DNA FRAGMENTATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY AFFINITY; ANTIGENS, CD20; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; INTERFERON-ALPHA; INTERFERON-BETA; LYMPHOMA, B-CELL; MICE; RECEPTOR, INTERFERON ALPHA-BETA; RECOMBINANT FUSION PROTEINS;

EID: 84880199055     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182993eb9     Document Type: Article

References (51)

1. Rodriguez-Villanueva J, McDonnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferonalpha. Int J Cancer. 1995;61:110-114.
2. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6:975-990.
3. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155-5161.
4. Borden EC. Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res. 2005;25: 511-527.
5. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307-336.
6. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol. 2002;71:565-581.
7. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8-32.
8. van Pesch V, Lanaya H, Renauld JC, et al. Characterization of the murine alpha interferon gene family. J Virol. 2004;78: 8219-8228.
9. Lamken P, Lata S, Gavutis M, et al. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol. 2004;341:303-318.
10. Kalie E, Jaitin DA, Podoplelova Y, et al. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem. 2008;283:32925-32936.
11. Lavoie TB, Kalie E, Crisafulli-Cabatu S, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011;56:282-289.
12. Borden EC, Lindner D, Dreicer R, et al. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol. 2000;10:125-144.
13. Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol. 1998;25:9-13.
14. Peleg-Shulman T, Tsubery H, Mironchik M, et al. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem. 2004;47: 4897-4904.
15. Talpaz M, O'Brien S, Rose E, et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001;98:1708-1713.
16. Rosendahl MS, Doherty DH, Smith DJ, et al. A long-acting, highly potent interferon alpha-2 conjugate created using sitespecific PEGylation. Bioconjug Chem. 2005;16:200-207.
17. Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma. 2006;47: 865-869.
18. Qin XQ, Tao N, Dergay A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA. 1998;95:14411-14416.
19. Dhodapkar KM, Dhodapkar MV. Recruiting dendritic cells to improve antibody therapy of cancer. Proc Natl Acad Sci USA. 2005;102:6243-6244.
20. Jazirehi AR, Huerta-Yepez S, Cheng G, et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005; 65:264-276.
21. Xuan C, Steward KK, Timmerman JM, et al. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010;115:2864-2871.
22. Betting DJ, Yamada RE, Kafi K, et al. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32:622-631.
23. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977;7:413-417.
24. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
25. Matsuuchi L, Morrison SL. Isolation and characterization of a variant of mouse plasmacytoma J558 synthesizing a 110,000-dalton immunoglobulin heavy chain and of secondary variants synthesizing either a 55,000-dalton or an 80,000-dalton immunoglobulin heavy chain: possible implications. Mol Cell Biol. 1982;2:1134-1144.
26. Oi V, Morrison SL. Chimeric antibodies. BioTechniques. 1986;4:214-221.
27. Scholzen T, Gerdes. J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
28. Salmon P, Le Cotonnec JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res. 1996;16:759-764.
29. Huang TH, Chintalacharuvu KR, Morrison. SL. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol. 2007;179: 6881-6888.
30. Pestka S, Kelder B, Familletti PC, et al. Molecular weight of the functional unit of human leukocyte, fibroblast, and immune interferons. J Biol Chem. 1983;258:9706-9709.
31. Sommereyns C, Michiels T. N-glycosylation of murine IFNbeta in a putative receptor-binding region. J Interferon Cytokine Res. 2006;26:406-413.
32. Senda T, Saitoh S, Mitsui Y. Refined crystal structure of recombinant murine interferon-beta at 2.15 A resolution. J Mol Biol. 1995;253:187-207.
33. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006;25:361-372.
34. Gamero AM, Potla R, Wegrzyn J, et al. Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem. 2006;281:16238-16244.
35. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000;256:12-18.
36. Janicke RU, Sprengart ML, Wati MR, et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998;273:9357-9360.
37. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res. 2001;7:1821-1831.
38. Yanase N, Ohshima K, Ikegami H, et al. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res. 2000;20:1121-1129.
39. Sondermann P, Huber R, Oosthuizen V, et al. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000;406:267-273.
40. Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol. 2001;309:737-749.
41. Yamada RE, Steward KK, Ngarmchamnanrith G, et al. Anti-CD20-interferon-a fusion protein demonstrates potent direct growth inhibition, antibody-dependent cellular cytotoxicity, and enhanced complement-dependent cytotoxicity against human b cell lymphomas in vitro, and activity against multiple human NHL xenografts in vivo. Blood (ASH Annual Meeting Abstracts). 2011;118:2724.
42. Tao MH, Canfield SM, Morrison. SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med. 1991;173:1025-1028.
43. TaoMH, Smith RI,Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 1993;178:661-667.
44. Sensel MG, Kane LM, Morrison SL. Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement. Mol Immunol. 1997;34:1019-1029.
45. Redpath S, Michaelsen T, Sandlie I, et al. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology. 1998; 93:595-600.
46. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178-4184.
47. Thommesen JE, Michaelsen TE, Loset GA, et al. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol Immunol. 2000;37:995-1004.
48. Hezareh M, Hessell AJ, Jensen RC, et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type. J Virol. 2001;75:12161-12168.
49. Zuckier LS, Chang CJ, Scharff MD, et al. Chimeric humanmouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo halflife. Cancer Res. 1998;58:3905-3908.
50. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23:2215-2223.
51. Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68:8384-8392.